MedTrace Logo

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

NCT06762964 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.

Conditions

  • Fontan Circulation
  • Single Ventricle Heart Disease
  • HFpEF - Heart Failure With Preserved Ejection Fraction

Interventions

DRUG

Dapagliflozin tablet

Patient will take a 10mg tablet of Dapagliflozin once daily for 12 weeks

DRUG

Placebo Tablet

Patient will take 10mg placebo tablet once daily for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Luke Burchill, M.B.B.S., Ph.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-16
Primary Completion
2027-02-28
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06762964 on ClinicalTrials.gov